Back to Search Start Over

Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.

Authors :
Segar, Matthew W.
Patel, Kershaw V.
Ayers, Colby
Basit, Mujeeb
Tang, W.H. Wilson
Willett, Duwayne
Berry, Jarett
Grodin, Justin L.
Pandey, Ambarish
Source :
European Journal of Heart Failure. Jan2020, Vol. 22 Issue 1, p148-158. 11p. 3 Charts, 3 Graphs.
Publication Year :
2020

Abstract

<bold>Aim: </bold>To identify distinct phenotypic subgroups in a highly-dimensional, mixed-data cohort of individuals with heart failure (HF) with preserved ejection fraction (HFpEF) using unsupervised clustering analysis.<bold>Methods and Results: </bold>The study included all Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) participants from the Americas (n = 1767). In the subset of participants with available echocardiographic data (derivation cohort, n = 654), we characterized three mutually exclusive phenogroups of HFpEF participants using penalized finite mixture model-based clustering analysis on 61 mixed-data phenotypic variables. Phenogroup 1 had higher burden of co-morbidities, natriuretic peptides, and abnormalities in left ventricular structure and function; phenogroup 2 had lower prevalence of cardiovascular and non-cardiac co-morbidities but higher burden of diastolic dysfunction; and phenogroup 3 had lower natriuretic peptide levels, intermediate co-morbidity burden, and the most favourable diastolic function profile. In adjusted Cox models, participants in phenogroup 1 (vs. phenogroup 3) had significantly higher risk for all adverse clinical events including the primary composite endpoint, all-cause mortality, and HF hospitalization. Phenogroup 2 (vs. phenogroup 3) was significantly associated with higher risk of HF hospitalization but a lower risk of atherosclerotic event (myocardial infarction, stroke, or cardiovascular death), and comparable risk of mortality. Similar patterns of association were also observed in the non-echocardiographic TOPCAT cohort (internal validation cohort, n = 1113) and an external cohort of patients with HFpEF [Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial cohort, n = 198], with the highest risk of adverse outcome noted in phenogroup 1 participants.<bold>Conclusions: </bold>Machine learning-based cluster analysis can identify phenogroups of patients with HFpEF with distinct clinical characteristics and long-term outcomes. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13889842
Volume :
22
Issue :
1
Database :
Academic Search Index
Journal :
European Journal of Heart Failure
Publication Type :
Academic Journal
Accession number :
141473562
Full Text :
https://doi.org/10.1002/ejhf.1621